DNDi was created in response to the frustration of clinicians and the desperation of patients faced with medicines that were ineffective, unsafe, unavailable, unaffordable, or that had never been developed at all.
Nearly two decades later, we have grown into a network of more than 200 partner institutions that spans the globe, united in our pursuit of science for the people, driven by collaboration, not competition, and by medical needs, not profits. Together, we have delivered eight new treatments that have saved millions of lives.
Now is the time to look ahead. As DNDi launches a new Strategic Plan, charting a journey to deliver 25 treatments in our first 25 years, we know we must brace ourselves for a decade of ever-increasing and changing needs. What will the next decade look like? How can we deliver on our commitments to people whose diseases have been historically overlooked by the traditional R&D model?
We joined a panel of passionate and committed experts to reflect on the challenges and drivers of change looming ahead.
- Dr Marie-Paule Kieny, Director of Research, INSERM and DNDi Board Chair
- Dr Bernard Pécoul, Executive Director, DNDi
- Dr Bernhards Ogutu, Chief Research Officer, KEMRI and DNDi Board Member
- Dr Jeremy Farrar, Director, Wellcome
- Dr Soumya Swaminathan, Chief Scientist, WHO
Moderated by Patricia Amira, Broadcaster